LAFAYETTE, Ind. -- Ash Access Technology, Inc. revealed more laboratory results today, adding anti-biofilm characteristics to previously reported antimicrobial results, thereby further strengthening MethLock's position as a serious contender to replace heparin in a $1 billion market.
"We plan to perform more rigorous tests, similar to the extensive tests we did to verify MethLock's antimicrobial attributes, but we are pleased with these first results," explains Roland K. Winger, vice president of engineering and quality assurance. "Since biofilm creates a friendly environment to host harmful bacteria associated with catheter-related
bloodstream infections (CRBSI), a key objective was to prevent biofilm growth. MethLock's anti-biofilm attributes help us understand its great potential for prevention of costly and deadly infection."
"These results just add to our growing excitement about the impact we expect MethLock to make toward saving lives threatened by catheter-related bloodstream infections," says Robert B. Truitt, president and CEO of Ash Access Technology, Inc. "By preventing biofilm buildup in catheters, and removing bacteria's favorite colonization grounds, we would expect to see a dramatic reduction in the billions of dollars estimated to be lost to these infections every year, (once our clinical trial is complete and we go to
market with MethLock in dialysis, oncology, and other chronic and acute
Ash Access Technology, Inc. is a privately held company founded to develop
antimicrobial and vascular access technologies, devices and methodologies to
combat the deadly and expensive problem of catheter-related bloodstream
infections (with an emphasis on prevention).
Source: Ash Access Technology, Inc.